evogene is a plant genomics company quoted on several major stock exchanges worldwide including the nyse.
the company utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity.
thanks to evogene’s unique technology infrastructure that is based on a deep scientific understanding of plant genomics, a complete solution for crop productivity improvement through biotechnology is available.
through its strategic collaborations with the world’s leading agricultural companies the company has developed improved seed traits with respect to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops such as corn, soybean, wheat and rice. in addition, evogene engages in earlier stage operations in agricultural chemicals and seeds for second generation feedstock for the biodiesel industry.
mr. ofer haviv, evogene’s ceo noted that during 2013 progress had been made on yield and abiotic stress largely thanks to the extension and expansion of its collaboration with the global concern monsanto. another area of activity where significant progress has been is biotic stress, where efforts are under way to cope with the damage done by other living organisms, whether these be bacteria, fungi, parasites or similar.
this is all part of the five year program which includes ongoing collaboration agreements with monsanto (extension of existing agreement), syngenta and du pont pioneer.
ofer haviv, evogene’s ceo expects to see that dedicated computer programs designed to enhance capabilities and assets in developing novel herbicides and crop enhancers will become a significant part of the company’s operations in the future. in concluding his remarks ofer haviv, evogene’s ceo stated confidently: “looking forward, to seeing our broadly applicable and continuously expanding technology infrastructure provide us with the foundation for substantial future growth in all of our current areas of focus.
” the company’s revenues increased marginally in 2013 while significant increases in research and development expenses as well as administrative and other costs led to an operating loss of 8.7 million dollars. however, the cash position remains strong at approximately 127 million dollars, largely reflecting the net proceeds of approximately $77 million from the recently completed equity offering in the us.